Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 13, 2026 14:09 ET | Source: Vanotech Ltd

Chengdu Origen and Vanotech Announce KHN921 Investigational New Drug application clearance by the US FDA for the treatment of hypertrophic cardiomyopathy (HCM) associated with MYBPC3 mutations

CHENGDU, China and ROCKAWAY, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- Chengdu Origen Biotechnology Co., Ltd. (“Chengdu Origen”) and Vanotech Ltd. (“Vanotech”) announced today that the US FDA granted...
May 13, 2026 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in Boston

SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Antonio F. Santidrian, PhD, Chief Scientific Officer and Head of Technical Operations for Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or...
May 12, 2026 08:40 ET | Source: Fortis Life Sciences

Fortis Life Sciences Awards 2026 AbNano® VHH Discovery Grant to Deliver Biosciences for Targeted Drug Delivery Research

Fortis Life Sciences awards Deliver Biosciences the 2026 AbNano® VHH Discovery Grant for in vivo CAR-T, gene therapy & nanoparticle drug delivery research
May 12, 2026 08:00 ET | Source: InVitria

InVitria Presents New Data at ASGCT 2026 on Recombinant Human Serum Albumin for Higher Lentiviral Vector Titers and Improved Cell Therapy Manufacturing

InVitria presents ASGCT 2026 data on recombinant albumin for improved lentiviral vector and cell therapy manufacturing.
May 11, 2026 08:00 ET | Source: AGC Biologics, Inc.

AGC Biologics Joins Orphan Therapeutics Accelerator’s Clinical Development Network as a Manufacturing Partner to Advance Cell and Gene Therapies for Ultra-Rare Diseases

The strategic alliance expands existing collaboration and strengthens OTXL’s ability to advance cell and gene therapies for ultra-rare conditions.
May 11, 2026 08:00 ET | Source: CPTx

CPTx appoints Edward Rebar as Chief Scientific Officer

Strengthening of CPTx executive team with appointment of Edward Rebar, PhD, as Chief Scientific Officer. David Maier is appointed Chief Business Officer.
May 07, 2026 09:03 ET | Source: SK pharmteco Inc.

SK pharmteco Collaborates with Axle Informatics and the National Institutes of Health to Advance Rare Disease Gene Therapy Programs

SK pharmteco partners with Axle Informatics and the National Institutes of Health (NIH) to advance the development of gene therapies for rare diseases.
May 05, 2026 08:32 ET | Source: Ocugen

Ocugen Provides Business Update with First Quarter 2026 Financial Results

Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p<0.05)...
May 05, 2026 08:12 ET | Source: Ocugen

Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes

MALVERN, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen”) (NASDAQ: OCGN) today announced the pricing of $115 million aggregate principal amount of 6.75% Convertible Senior Notes due...
May 05, 2026 07:05 ET | Source: uniQure Inc.

uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates

~ Advancing FDA interactions on AMT-130 for Huntington’s disease; Type B meeting scheduled for the second quarter of 2026 ~ ~ Progressing AMT-130 toward expected UK regulatory submission; MAA on...